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Abstract
Background: Long-term outcomes in non-HIV immunocompromised patients with disseminated Mycobacterium
avium complex (dMAC) infections are unknown and the need for post-treatment secondary prophylaxis against
MAC is uncertain in this setting. The objective of this study was to determine the need of continuing secondary
anti-MAC prophylaxis in non-HIV patients after completing treatment of the primary dMAC episode.
Methods: We conducted a ten-year multi-center analysis of non-HIV immunosuppressed patients with dMAC
infections in Hong Kong.
Results: We observed sixteen patients with dMAC during the study period of which five (31 %) were non-HIV
immunosuppressed patients. In the non-HIV immunosuppressed group, three patients completed a treatment
course without secondary prophylaxis, one patient received azithromycin-based secondary prophylaxis and one
patient was still receiving therapy for the first dMAC episode. All the three patients who completed treatment
without being given secondary prophylaxis developed recurrent dMAC infection requiring retreatment.
Conclusions: In view of the high rate of dMAC infection recurrence in non-HIV immunocompromised patients
following treatment completion, our data support long-term anti-MAC suppression therapy after treatment of the
first dMAC infection episode in immunocompromised non-HIV patients, as is recommended for patients with
advanced HIV. Tests of cell mediated immune function need to be evaluated to guide prophylaxis discontinuation in
non-HIV patients.
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Background
Disseminated Mycobacterium avium complex (dMAC) in-
fection is indicative of profound cell-mediated immuno-
deficiency and is best described in the setting of advanced
HIV disease. However, with an expanding population of
immunosuppressed patients worldwide, dMAC infections
in the non-HIV population are increasingly being recog-
nized in the scientific literature. Organ transplantation,
immunosuppressants, novel immunomodulatory agents,
autoimmune disorders, autoantibodies against interferon
(IFN)-γ and hereditary immunological defects have all
been associated with dMAC infection in HIV-negative in-
dividuals [1–7]. As the incidence of dMAC infection in
the HIV-infected population declines due to effective
combined antiretroviral therapy (cART) and anti-MAC
primary and secondary prophylaxis [8], infections in the
non-HIV population are likely to constitute an increasing
proportion of the overall dMAC disease burden.
In HIV-positive patients with dMAC disease who re-
spond to anti-MAC therapy, current guidelines advise the
continuation of anti-MAC treatment as post-treatment
suppression (secondary prophylaxis) until sustained CD4+
T-lymphocyte recovery to >100 cells/μL is achieved using
combined antiretroviral therapy [9]. The anti-mycobacterial
treatment regimens for non-HIV patients with dMAC in-
fection are extrapolated from clinical experience in the HIV
setting. However, the need for secondary prophylaxis to
prevent dMAC infection recurrence after treatment
completion remains a largely unaddressed issue in these
patients. This is partly because anti-MAC prophylaxis
recommendations for HIV patients are based on CD4+
T-lymphocyte measurements [9, 10] and cannot be eas-
ily applied to non-HIV patients who often suffer from
diverse functional cell-mediated immune defects that
are not easily quantified in routine clinical practice.
Furthermore, a systematic description of long-term out-
comes in non-HIV dMAC infection case cohorts is
lacking and the rate of recurrence is unknown.
We addressed this issue by analyzing the epidemiology
of patients with dMAC infections over a ten-year period
in a multi-center study. We evaluated the outcomes of
non-HIV patients with dMAC infection to determine
the need for post-treatment secondary prophylaxis in
non-HIV patients, as recommended in the HIV setting.
Methods
This study was approved by the Institutional Review
Board of The University of Hong Kong/ Hospital Author-
ity Hong Kong West Cluster. Permission for retrospective
data retrieval from clinical databases and waiver for in-
formed consent were approved by the Institutional Review
Board. We analyzed the records of patients with dMAC
infections presenting between 2005 and 2014 to four pub-
lic hospitals in Hong Kong. All four hospitals offer acute
internal medicine services and one is a university teaching
hospital providing hematopoietic stem cell and solid organ
transplantation services. Patients were diagnosed with
dMAC infection based on compatible clinical features
and isolation of MAC from blood, bone marrow and/
or other extrapulmonary sterile sites. Patients with sus-
pected specimen contamination who were not offered
anti-mycobacterial treatment (e.g. single positive early
morning urine culture) were excluded from the ana-
lysis. The clinical records of patients who fulfilled the
inclusion criteria were examined in detail for demo-
graphic features, risk factors for opportunistic infec-
tions, clinical features, anti-mycobacterial regimen,
prescription of anti-MAC secondary prophylaxis and
long-term outcomes.
Results
Sixteen patients fulfilling the criteria for dMAC infec-
tion were identified over the ten-year period. Five of
sixteen (31 %) patients with dMAC infection were HIV-
negative immunosuppressed patients, while the other
eleven patients had HIV-AIDS. The clinical features of
the non-HIV immunosuppressed patients with dMAC
infection are summarized in Table 1 and described in
detail below.
Patient 1
An 85-year-old man, with history of ischemic heart
disease and monoclonal gammopathy, presented with
fever, cough and atypical chest pain. Chest radiography
showed an ill-defined shadow in the upper parame-
diastinal region with cortical disruption of sternum.
Computed tomography (CT) of the thorax confirmed a
presternal mass along with a spiculated soft tissue
mass in the posterior segment of the right upper lobe.
Histology of the presternal mass showed a chronic in-
flammatory infiltrate and was positive for acid-fast ba-
cilli (AFB) by Ziehl-Neelsen (ZN) stain. Biopsy tissue
and sputum both yielded MAC. The patient was
started on clarithromycin, ethambutol and rifampicin.
He competed 11 months of anti-MAC treatment,
responding well with sputum culture conversion and
radiological improvement.
Ten months after cessation of therapy, he presented
again with fever, weight loss, skin nodules and general-
ized lymphadenopathy. Sputum and skin biopsy yielded
MAC. dMAC disease or an underlying lymphoma were
considered to be the cause of the generalized lymph-
adenopathy, however the patient declined further inva-
sive investigations due to debilitated condition and
advanced age. He was restarted on clarithromycin, ri-
fampicin and ethambutol, but eventually succumbed.
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Table 1 Clinical features and outcomes in non-HIV patients with disseminated MAC infections
Agea/sex Underlying conditions Presenting signs/symptoms Site of MAC isolation Treatment regime
and duration
Time to
recurrenceb
Site of MAC
at recurrence
Outcomec
1 85/M Monoclonal gammopathy of
undetermined significance
Fever, pain over sternum Sternal mass biopsy
tissue, sputum
Clarithromycin, ethambutol
and rifampicin for 11 months
10 months Skin nodules,
sputum
Restarted on clarithromycin,
ethambutol and rifampicin;
died during treatment due
to suspected lymphoma
2 43/F Systemic lupus erythematosus
on azathioprine
Fever, per vaginal bleeding,
cutaneous nodules over legs,
groin lymphadenopathy
High vaginal swab,
groin lymph node,
skin biopsy
Clarithromycin, ethambutol
and rifampicin for 21 months
3 years Bone marrow,
femoral bone,
knee joint fluid
Repeat course of clarithromycin,
ethambutol and rifampicin; still
receiving treatment
(as of March 2015)
3 67/Fd Autoantibody against IFN-γ,
paraproteinemia
Fever Blood, bone marrow Azithromycin, ethambutol
and rifampicin for
24 monthsAzithromycin
secondary prophylaxis
No dMAC
recurrence
N/A Developed lymphoma and
died 9 months after completion
of anti-MAC treatment
4 42/F Autoantibody against IFN-γSjogren’s
syndrome, autoimmune myelofibrosis
on prednisolone and mycophenolate
mofetil
Fever, night sweats, pain
over sternum
Sternal bone aspirate Clarithromycin, ethambutol
and rifampicin for 12 months
1 year Blood, sputum Repeat course of clarithromycin,
ethambutol and rifampicin; still
receiving treatment
(as of March 2015)
5 43/F Autoantibody against IFN-γSystemic
lupus erythematosus, mixed
connective tissue disease
Fever, cough Bone marrow, lung
biopsy, sputum
Clarithromycin, ethambutol
and rifampicin; still receiving
treatment (as of March 2015)
N/A N/A Radiological improvement in
consolidative changes of left
lung on interval imaging
aage at diagnosis of dMAC infection
btime to recurrence refers to duration between completion of treatment of primary dMAC episode to symptom onset of the recurrent episode
cpatients were followed up from time of diagnosis of primary dMAC episode till time of writing—March 2015
dadopted from reference
Sridhar
et
al.BM
C
Infectious
D
iseases
 (2016) 16:74 
Page
3
of
6
Patient 2
A 43-year-old woman, with background history of sys-
temic lupus erythematosus (SLE) on azathioprine, pre-
sented with pervaginal bleeding, enlarged left groin lymph
node and indurated erythematous lesions over the lower
limbs. Groin lymph node biopsy showed granulomatous
inflammation with numerous AFB. The patient’s high va-
ginal swab and swabs from lower limb lesions both yielded
MAC. HIV antibody was negative. She was started on ri-
fampicin, clarithromycin and ethambutol.
Staging positron emission tomography—computed tom-
ography (PET-CT) after fourteen months of anti-MAC
treatment showed multiple soft tissue nodules of both
lungs although histology and microbiology of specimens
from these sites did not detect any AFB. In view of
radiological suspicion of ongoing dMAC infection and
immunosuppressed state, she received 21 months of anti-
MAC treatment in total with end-of-treatment PET-CT
documenting resolution of lung lesions and lymphadenop-
athy. She presented three years after cessation of treat-
ment with recurrent dMAC infection involving the bone
marrow, left distal femur and knee joint. She required re-
peated debridement and sequestrectomy of infected bone
and knee joint and was treated with clarithromycin, rifa-
butin, ethambutol and moxifloxacin.
Patient 3
A 67-year-old woman with good past health presented
with pyrexia of unknown origin. PET-CT imaging showed
multiple hypermetabolic active lesions over bilateral lung
fields and generalized lymphadenopathy. Bone scintig-
raphy further showed multifocal active lesions in the
vertebral column, bilateral ribs and right clavicle. Cul-
tures of blood and bone marrow yielded MAC and she
received a regimen containing azithromycin, rifampicin
and ethambutol. She was confirmed to have autoanti-
body against IFN-γ.
Treatment was continued for two years and then
switched to long-term secondary prophylaxis with azi-
thromycin. She died due to lymphoma nine months after
completing the multi-drug regimen for dMAC. Sputum,
blood and urine cultures for acid-fast bacilli obtained be-
fore death were negative.
Patient 4 (this patient was also described in reference 4)
A 42-year-old woman with background history of Sjogren’s
syndrome and myelofibrosis, receiving mycophenolate mo-
fetil and prednisolone 25 mg daily, presented with a sternal
soft tissue mass. Fine needle aspiration cytology from the
mass lesion was compatible with mycobacterial infection.
Culture of the pus yielded MAC. PET-CT imaging showed
hypermetabolic precarinal lymphadenopathy and extensive
osseous hypermetabolic lesions involving multiple verte-
brae, left scapula, sternum, right humeral head, bilateral
ribs, ilia and pubic rami indicative of dMAC. Autoantibody
against IFN-γ was positive.
She was started on a regimen comprising ethambutol,
clarithromycin and rifampicin, completing one year of
treatment with resolution of osseous lesions on re-
assessment imaging. One year after completing treat-
ment, she presented with pyrexia of unknown origin.
PET-CT showed a cavitatory lesion in upper lobe of left
lung. Blood and sputum both yielded MAC; she was
restarted on clarithromycin, rifampicin and ethambutol
with good clinical response.
Patient 5
A 43-year-old woman with SLE and mixed connective
tissue disease presented with fever and cough for one
month. CT of the thorax showed a left upper lobe mass
lesion. Bronchoscopic biopsy of the lesion revealed a
mixed active chronic inflammatory infiltrate with foci of
granulomatous inflammation. AFB were demonstrated
by ZN stain. Bone marrow examination was also per-
formed in view of anemia (Hemoglobin: 6.8 g/dL) and
leukocytosis (WBC: 36.29 × 109/L) showing hypercellular
marrow with mature plasma cells. Multiple sputum
specimens, bronchial tissue and bone marrow yielded
MAC confirming the diagnosis of dMAC.
As she was not on immunosuppressive treatment at
presentation, immunological workup was performed con-
firming that she had autoantibody against IFN-γ.. She was
started on clarithromycin, rifampicin and ethambutol;
treatment of this patient is ongoing with good clinical and
radiological response.
Discussion
In this ten-year multi-center study that identified sixteen
patients with dMAC, non-HIV patients accounted for ap-
proximately one-third (5/16) of all patients with dMAC
infection over the study period, which constitutes a signifi-
cant proportion of the overall dMAC disease burden in
our setting. This finding is in sharp contrast to previous
studies involving disseminated non-tuberculous mycobac-
terial disease cohorts conducted more than 15 years ago,
which found that dMAC infections were almost entirely
encountered in HIV-positive patients [11, 12]. With the
fall in dMAC infection incidence in HIV carriers and the
increasing population of non-HIV immunocompromised
patients, it is expected that an increasing proportion of all
dMAC infections will occur in non-HIV patients as was
observed in our cohort.
This is the first systematic analysis of long-term out-
comes in a non-HIV dMAC patient cohort. We found that
all three non-HIV immunocompromised patients who
were not prescribed secondary anti-MAC prophylaxis de-
veloped recurrent dMAC infection after treatment comple-
tion. Among the eleven HIV-positive dMAC patients, five
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completed treatment for the first dMAC episode while six
died during the treatment period due to other oppor-
tunistic infections and malignancy. In contrast to the
non-HIV patient group, none of the five HIV-positive
patients who completed treatment for the first dMAC
infection episode and received cART developed recur-
rence (data not shown). This finding is especially im-
portant as there is a lack of recommendations for
secondary anti-MAC prophylaxis in the non-HIV im-
munocompromised population following treatment
completion of the first episode of dMAC infection.
Based on the results of our study, we believe that pa-
tients with profound immunosuppression are likely to
benefit from long-term secondary prophylaxis against
MAC after treatment completion unless their immuno-
logical dysfunction is temporary and reversible. How-
ever, due to the heterogeneity of immunosuppressive
conditions predisposing to dMAC infection in non-HIV
patients, large clinical trials evaluating different
prophylaxis strategies are likely to be infeasible. There-
fore, we recommend that patients who have completed
a course of anti-MAC therapy but deemed to have on-
going severe immunosuppression (e.g. high immuno-
suppressant dosages, primary immunodeficiencies, low
CD4+ counts) should be continued on oral azithromy-
cin and ethambutol as secondary prophylactic agents
until such time as restoration of immunological func-
tion is achievable. This regimen of secondary prophy-
laxis has been shown to be safe and well tolerated in
the HIV population. To reduce pill burden and improve
patient compliance, azithromycin monotherapy for sec-
ondary prophylaxis may be considered for some pa-
tients who are deemed to be at ongoing risk for
opportunistic infections but have improving immuno-
logical function (such as transplant recipients on taper-
ing dose of immunosuppressants), but this strategy
carries a risk of selecting out macrolide resistance in
any residual MAC and, if used, should follow a duration
of two-drug suppressive therapy. Breakthrough dMAC
disease while on macrolide monotherapy prophylaxis
should prompt clarithromycin susceptibility testing and
an empirical dMAC treatment regimen that includes at
least three antimycobacterial drugs active against MAC.
Long term secondary prophylaxis may not be necessary
in immunosuppressed patients with localized infection;
we identified one patient who developed sternal osteo-
myelitis due to MAC without evidence of dissemination
(unpublished data). She had no recurrence at ten years
follow up despite not receiving secondary prophylaxis.
Currently, there is insufficient evidence for primary
anti-MAC prophylaxis in any non-HIV immunocom-
promised group, but this may be a consideration in pa-
tients with newly diagnosed anti-IFN-γ autoantibodies,
a common risk factor for dMAC infection in our study.
In addition to quantitative counts of CD4+ T-
lymphocytes, tests of T-lymphocyte function are re-
quired in routine clinical practice to objectively assess
cell mediated immunological function of patients at
treatment completion of dMAC to guide prophylaxis
decisions. While classical lymphocyte proliferation
assays are labor intensive and require specialist labora-
tory support, the clinical utility of newer tests of T-
lymphocyte function such as the ImmuKnow assay
(ViraCor-IBT, USA) and flow cytometry based prolifer-
ation assays are being explored [13, 14]. The role of
monitoring markers of cell-mediated immunity to
guide anti-MAC prophylaxis discontinuation in non-
HIV populations deserves further evaluation.
Conclusions
Recurrence of dMAC infections after treatment completion
was very common in non-HIV immunosuppressed pa-
tients, warranting the consideration of post-treatment sec-
ondary prophylaxis as in their HIV-positive counterparts.
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